Results in 7 days for DNA, 10 days for RNA tests
Evolving oncology diagnosis, prognosis and precision medicine
Cancer is a complex disease requiring comprehensive answers. Only a comprehensive answer will allow medical professionals to make the highest quality care decisions for their patients. At GTC we analyze both DNA and RNA which gives the best possible answers based on our current knowledge.
GTC Provides Comprehensive Answers
Both solid tumors (lung, colon, breast, etc) and hematologic malignancies (leukemia, multiple myeloma, etc) have molecular profiling tests available.
All major types of cancer have molecular testing that can be performed on them but the sample requirements will be different.
Genomic Testing Cooperative is creating a new kind of disruptive business model. We utilize advanced next-generation sequencing techniques and AI to offer the most innovative testing to our customers. Our co-op allows customers to select a level of service that suits their oncology testing requirements including:
1. An in-house genomics lab managed by GTC
2. Cooperative Associate
3. Client
Genomic testing is expensive and risky for smaller labs because of its complexity and rapidly changing information. Competing with larger labs is challenging to get scale for profitable operations and will face different billing challenges than routine tests.
GTC alleviates those risks and challenges for our customers handling innovation, medical oversight, operations, and billing.
GTC has created a co-op model to reduce sales, operations, and service costs – the biggest impediment to profitability by sharing resources. We have a level of membership that works for the smallest labs up to the biggest reference labs.
To learn more reach out for a capabilities presentation.
Most labs work on a basis where a lab sends a sample and the lab bills either the hospital or the patient. The relationship is purely transactional.
GTC allows members to join, share resources, share knowledge, have a voice in GTC, and collaborate in a community environment. The Co-op model produces big data for AI analysis creating value for hospitals, research, drug development, and other involved in cancer care.
GTC works with laboratories, hospitals, pathologists, oncologists, and other medical professionals to improve access to cutting edge technology at an affordable price by sharing resources and expertise.
Gain access to advanced technology, molecular expertise, and a pipeline for innovation and development of new tests.
GTC utilizes technology innovations that integrate artificial intelligence and proprietary algorithms within our informatics tools. These tools enable faster turnaround times of results, comprehensive reporting including targeted and immunotherapy recommendations and clinical trial options.
Learn more about the GTC Co-Op model
Machine/Deep learning meets next generation sequencing
Genomic sequencing revolutionary methods never used before. Next generation sequencing has changed medicine in the past decade in ways most people couldn’t imagine. It has allowed a rapid evolution to the field of precision medicine with new drugs being approved regularly.
A cooperation model of bringing new solutions. Simply put a Co-Op means we all work together as a team to make things better. In the case of the Genomic Testing Cooperative it means that our lab works with other labs, physicians and patients to improve the communities access to cutting edge healthcare.
Our AI helps us sort through curate large sets of data so we can quickly make sense of genomic alterations and assess their impact on a patient prognosis, diagnosis and help predict their response to therapy. We use machine learning to review these alterations and track their frequency.
Machine/deep Learning meets Next Generation Sequencing
Genomic sequencing revolutionary methods never used before. Next generation sequencing has changed medicine in the past decade in ways most people couldn’t imagine. It has allowed a rapid evolution to the field of precision medicine with new drugs being approved regularly.
A Cooperation Model of Bringing new solutions. Simply put a co-op means we all work together as a team to make things better. In the case of the Genomic Testing Cooperative it means that our lab works with other labs, physicians and patients to improve the communities access to cutting edge healthcare.
Our AI helps us sort through curate large sets of data so we can quickly make sense of genomic alterations and assess their impact on a patient prognosis, diagnosis and help predict their response to therapy. We use machine learning to review these alterations and track their frequency.
The Medicare Administrative Contractor Palmetto GBA (MolDx®) has finalized its review and has established coverage for two Genomic Testing Cooperative (GTC) hematology profiles: GTC-Hematology (177 gene DNA profiling) and GTC-Hematology Plus (177 gene DNA and 1408 gene RNA profiling).
The two Comprehensive Genomic Profile (CGP) tests are designed to help Pathologists and Hematologists/Oncologists in establishing the precise diagnosis, prognosis and determine therapy in hematologic neoplasms.
The GTC Hematology test (177 gene DNA Profile) can be performed on cell-free DNA (cf-DNA) from peripheral blood samples representing the first Palmetto GBA covered liquid biopsy for hematology. A liquid biopsy for suspected hematologic neoplasms or monitoring patients with hematologic neoplasms can be highly useful and practical as a replacement to the painful bone marrow biopsy, which can be a deterrent for some patients.
Or Contact us today at 949-540-9421 to order and learn more about our NGS offering.
Get Results in 7 days.
Pain free
Non-Invasive
Fast
Accurate
Α detailed interview
Next generation sequencing has changed medicine in the past decade in ways most people couldn’t imagine. It has allowed a rapid evolution to the field of precision medicine with new drugs with being approved regularly. However, it has previously been cost prohibitive with many insurance companies not covering testing. The data sets it produced were also hard to interpret and understand due to their size, complexity and lack of historical data.
We have now reached a time where we can utilize genomic testing in a cost-effective matter. The tools are now available to make sense of the complex data. There is a large database of samples to look at and compare. In essence, we are at the tipping point of a deep understanding of cancer which we have never had before in human history and are making therapies that have the potential to cure the disease.
GTC Advanced Genomic Testing
Thank you for taking the time to read this page.
Cancer is a genomic disease and understanding what is happening at a genomic level helps medical professionals provide better care.
Get all the critical news and events sent straight to your inbox.
Get all the critical news and events sent straight to your inbox.
Let’s talk